Quinoline-based Compounds with Potential Activity against Drugresistant Cancers
- 10 March 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 21 (5), 426-437
- https://doi.org/10.2174/1568026620666200618113957
Abstract
Drug resistance is the major cause of the failure of cancer chemotherapy, so one of the most important features in developing effective cancer therapeutic strategies is to overcome drug resistance. Quinoline moiety has become one of the most privileged structural motifs in anticancer agent discovery since its derivatives possess potent activity against various cancers including drug-resistant cancers. Several quinoline-based compounds which are represented by Anlotinib, Bosutinib, Lenvatinib, and Neratinib have already been applied in clinical practice to fight against cancers, so quinoline-based compounds are potential anticancer agents. The present short review article provides an overview of the recent advances of quinoline-based compounds with potential activity against drug-resistant cancers. The structure-activity relationship and mechanisms of action are also discussed.Funding Information
- Inner Mongolia Natural Science Foundation (2019MS08197)
This publication has 85 references indexed in Scilit:
- Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant CellsPLOS ONE, 2012
- Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial CarcinomasPLOS ONE, 2012
- CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination TherapyMolecular Cancer Therapeutics, 2012
- The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In VivoPLOS ONE, 2011
- Synthesis and Biological Evaluation of 4-Aroyl-6,7,8-Trimethoxyquinolines as a Novel Class of Anticancer AgentsMolecules, 2011
- Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of CancerJournal of Medicinal Chemistry, 2010
- CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor EfficacyCancer Research, 2010
- Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic LeukemiaCancer Research, 2010
- Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase IIPLOS ONE, 2010
- Cancer Chemotherapy by Liposomal 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one Dihydrochloride (TAS-103), a Novel Anti-cancer Agent.Biological & Pharmaceutical Bulletin, 2002